Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mesoblast ( (MESO) ) has shared an announcement.
On September 26, 2025, Mesoblast Limited announced that its allogeneic cell therapy products, including Ryoncil®, are designated as U.S. origin products and are not subject to tariffs on imported branded or patented pharmaceutical products. This designation aligns with U.S. FDA and Customs regulatory guidance, ensuring that Mesoblast’s products remain competitive in the market. The announcement underscores Mesoblast’s commitment to manufacturing its therapies from U.S. donors at U.S. sites, which is crucial for maintaining its market position and operational efficiency. This development is significant for stakeholders as it reinforces the company’s strategic positioning in the global market for cellular medicines.
The most recent analyst rating on (MESO) stock is a Hold with a $17.50 price target. To see the full list of analyst forecasts on Mesoblast stock, see the MESO Stock Forecast page.
Spark’s Take on MESO Stock
According to Spark, TipRanks’ AI Analyst, MESO is a Neutral.
Mesoblast’s overall stock score is driven by its strong technical momentum, which is offset by weak financial performance and valuation metrics. The company’s significant revenue growth and market access achievements are promising, but profitability challenges and a negative P/E ratio weigh heavily on the score.
To see Spark’s full report on MESO stock, click here.
More about Mesoblast
Mesoblast Limited is a global leader in the development of allogeneic cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company specializes in therapies derived from mesenchymal lineage cell therapy technology, which release anti-inflammatory factors to modulate the immune system. Mesoblast’s flagship product, Ryoncil®, is the first FDA-approved mesenchymal stromal cell therapy for pediatric patients with steroid-refractory acute graft versus host disease (SR-aGvHD). The company operates in Australia, the United States, and Singapore, and is listed on the Australian Securities Exchange and Nasdaq.
Average Trading Volume: 260,364
Technical Sentiment Signal: Strong Buy
Current Market Cap: $2.01B
See more data about MESO stock on TipRanks’ Stock Analysis page.